William C. Ports

684 total citations
21 papers, 534 citations indexed

About

William C. Ports is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, William C. Ports has authored 21 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Dermatology, 13 papers in Immunology and Allergy and 6 papers in Physiology. Recurrent topics in William C. Ports's work include Dermatology and Skin Diseases (17 papers), Allergic Rhinitis and Sensitization (10 papers) and Food Allergy and Anaphylaxis Research (6 papers). William C. Ports is often cited by papers focused on Dermatology and Skin Diseases (17 papers), Allergic Rhinitis and Sensitization (10 papers) and Food Allergy and Anaphylaxis Research (6 papers). William C. Ports collaborates with scholars based in United States, Australia and United Kingdom. William C. Ports's co-authors include Vivek S. Purohit, Cunshan Wang, Michael A. Zielinski, Robert Bissonnette, Chuanbo Zang, Bonnie Vlahos, John L. Werth, Kim Papp, Zoé Kececioglu Draelos and Huaming Tan and has published in prestigious journals such as Circulation, Journal of Allergy and Clinical Immunology and Journal of Lipid Research.

In The Last Decade

William C. Ports

21 papers receiving 518 citations

Peers

William C. Ports

DERMA

IMMUN

RHEUM

PHYSI

Nicole Dumont United States

Dennis Brinker United States

Paola Facheris Italy

Luca Mastorino Italy

Vincenzo Picone Italy

Jorge R. Georgakopoulos Canada

Momoko Kimishima Japan

M. Ruer‐Mulard France

Gaia Moretta Italy

Mark Anliker Switzerland

Nicole Dumont United States

William C. Ports

329 ×0.9

DERMA

115 ×0.5

285 ×1.7

IMMUN

102 ×0.7

RHEUM

89 ×1.0

PHYSI

Citations per year, relative to William C. Ports William C. Ports (= 1×) peers Nicole Dumont

Countries citing papers authored by William C. Ports

Since Specialization

Citations

This map shows the geographic impact of William C. Ports's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Ports with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Ports more than expected).

Fields of papers citing papers by William C. Ports

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William C. Ports. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Ports. The network helps show where William C. Ports may publish in the future.

Co-authorship network of co-authors of William C. Ports

This figure shows the co-authorship network connecting the top 25 collaborators of William C. Ports. A scholar is included among the top collaborators of William C. Ports based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William C. Ports. William C. Ports is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luger, Thomas A., Adelaide A. Hebert, Andrea L. Zaenglein, et al.. (2022). Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years. Pediatric Drugs. 24(2). 175–183. 13 indexed citations

Draelos, Zoé Kececioglu, et al.. (2020). Skin permeation and penetration of crisaborole when coapplied with emollients. Journal of the American Academy of Dermatology. 83(6). 1801–1803. 8 indexed citations

Schlessinger, Joel, Richard Gower, John Su, et al.. (2020). Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). American Journal of Clinical Dermatology. 21(2). 275–284. 66 indexed citations

Purohit, Vivek S., Steve Riley, Huaming Tan, & William C. Ports. (2020). Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis. The Journal of Clinical Pharmacology. 60(10). 1344–1354. 6 indexed citations

Bissonnette, Robert, Ana B. Pavel, Aisleen Diaz, et al.. (2019). Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial. Journal of Allergy and Clinical Immunology. 144(5). 1274–1289. 95 indexed citations

Callender, Valerie, Andrew Alexis, Linda Stein Gold, et al.. (2019). Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. American Journal of Clinical Dermatology. 20(5). 711–723. 36 indexed citations

Draelos, Zoé Kececioglu, Steven R. Feldman, Brian Berman, et al.. (2019). Tolerability of Topical Treatments for Atopic Dermatitis. Dermatology and Therapy. 9(1). 71–102. 21 indexed citations

Yoshida, Mizuki, et al.. (2019). Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis. The Journal of Dermatology. 47(1). 25–32. 10 indexed citations

Eichenfield, Lawrence F., Thomas A. Luger, Kim Papp, et al.. (2019). Topical Agents for the Treatment of Atopic Dermatitis. Journal of Drugs in Dermatology. 19(1). 50–64. 6 indexed citations

10.

Nash, Peter, Laura C. Coates, Roy Fleischmann, et al.. (2018). Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatology and Therapy. 5(2). 567–582. 34 indexed citations

11.

Yosipovitch, Gil, Eric L. Simpson, Huaming Tan, et al.. (2018). Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials. 3(2). e12–e12. 7 indexed citations

12.

Purohit, Vivek S., William C. Ports, Cunshan Wang, & Steve Riley. (2018). Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning. The Journal of Clinical Pharmacology. 59(6). 811–820. 29 indexed citations

13.

Yosipovitch, Gil, Eric L. Simpson, Andrew G. Bushmakin, et al.. (2018). Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS). 3(2). e13–e13. 13 indexed citations

14.

Zhang, Jianzhong, Tsen‐Fang Tsai, Min‐Geol Lee, et al.. (2017). The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study. Journal of Dermatological Science. 88(1). 36–45. 75 indexed citations

15.

Ports, William C., Rana Fayyad, David A. DeMicco, Rachel Laskey, & Robert Wołk. (2017). Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clinical Drug Investigation. 37(8). 775–785. 25 indexed citations

16.

Simpson, Eric L., Andrew G. Bushmakin, Joseph C. Cappelleri, et al.. (2017). Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis. SKIN The Journal of Cutaneous Medicine. 1. s36–s36. 3 indexed citations

17.

Yosipovitch, Gil, Eric L. Simpson, Huaming Tan, et al.. (2017). The Effect of Crisaborole Ointment, 2%, on Pruritus in Patients with Atopic Dermatitis: An Extended Analysis. SKIN The Journal of Cutaneous Medicine. 1. s39–s39. 1 indexed citations

18.

Papp, Kim, Robert Bissonnette, Melinda Gooderham, et al.. (2016). Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatology. 16(1). 76 indexed citations

19.

Barter, Philip J., Kerry‐Anne Rye, Mohan Beltangady, et al.. (2012). Relationship between atorvastatin dose and the harm caused by torcetrapib. Journal of Lipid Research. 53(11). 2436–2442. 7 indexed citations

20.

Shear, Charles L., Mohan Beltangady, William C. Ports, William Duggan, & Philip J. Barter. (2008). Abstract 1694: Torcetrapib: Predictors of Increased Clinical Risk in the Illuminate Study. Circulation. 118(3). e2667–e2667. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact